Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: Could surrogate indexes identify insulin resistant individuals among women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Surrogate indexes may be able to rule in, but not rule out, insulin resistance in women with PCOS. WHAT IS KNOWN ALREADY: Insulin resistance is a typical finding of women with PCOS and most clinical information on this issue is based upon surrogate indexes of insulin resistance. However, data on the performance of these indexes in PCOS women are very limited. STUDY DESIGN SIZE, DURATION: A retrospective analysis of 406 women referred to our outpatient clinic for hyperandrogenism and/or menstrual dysfunction and submitted to hyperinsulinemic euglycaemic clamp between 1998 and 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 375 of these women had PCOS by the Rotterdam criteria and were included in the study. Six surrogate indexes of insulin sensitivity were calculated from glucose and insulin levels, either at fasting (homeostasis model assessment (HOMA), glucose/insulin (G/I) ratio and quantitative insulin sensitivity check index (QUICKI)) or after oral glucose load (Gutt, Stumvoll0-120 and Matsuda). MAIN RESULTS AND THE ROLE OF CHANCE: Overall, insulin resistance, as identified by the M-clamp value, was found in 74.9% of these women. The percentage was 59.3% in normal-weight vs 77.5% in overweight and 93.9% in obese subjects. All surrogate indexes were highly correlated with the M-clamp values. However, their ability to identify insulin resistant individuals was limited, in terms of sensitivity and especially in normal-weight subjects. ROC analysis showed similar performances of these indexes (AUC values 0.782-0.817). LIMITATIONS REASONS FOR CAUTION: Potential referral bias of PCOS patients may have caused overestimation of the prevalence of insulin resistance in these women. WIDER IMPLICATIONS OF THE FINDINGS: By using surrogate indexes many subjects with PCOS may be erroneously diagnosed as insulin sensitive, especially among normal-weight women. These indexes can be used to rule in, but not rule out, insulin resistance in PCOS. STUDY FUNDING/COMPETING INTEREST(S): Academic grants to P. Moghetti from the University of Verona. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with nearly 75% of individuals with PCOS estimated to have some degree of insulin resistance [27].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [27]
In the citing paper
“Insulin resistance appears to be a large driver of these risk factors”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [27]
In the citing paper
“In actual fact, they are more valuable in ruling in rather than ruling out insulin resistance in PCOS, especially among normal weight women [43].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [43]
In the citing paper
“In PCOS, IR is present in obese and overweight patients, as well as in those of normal weight, although in the latter group, with a lower frequency (59.3% in normal weight vs. 77.5% in overweight and 93.9% in obese patients) [33].”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [33]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 1×
“Diagnosis of metabolic syndrome was carried out using the 2009 joint criteria by the International Diabetes Federation (IDF) and other Societies (Alberti et al., 2009).”
Method(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 1×
“Glucose disposal rate during the steady-state period of the clamp (M-clamp) was calculated with standard formula (DeFronzo et al., 1979).”
MethodMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“…in other clinical conditions, suggested that surrogate indexes derived from the OGTT could perform better, as compared with those obtained from fasting values (Matsuda and DeFronzo, 1999; Gutt et al., 2000; Stumvoll et al., 2001), although the amount of additional information may indeed be limited.”
BackgroundKatz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 1×
“Because muscle is responsible for most insulin-induced glucose metabolism (DeFronzo, 1988), glucose disposal data were expressed per fat-free mass (mg/kg FFMmin).”
BackgroundMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“Second, insulin resistance plays a crucial role in the pathogenesis of PCOS itself (Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundHirsutism: Implications, etiology, and management
Hatch, R., Rosenfield, R. L., Kim, M. H., & Tredway, D. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90746-8 · Cited by 1,014 · cited 2×
“Clinical hyperandrogenism was defined by the presence of hirsutism (modified Ferriman–Gallwey score ≥8) (Hatch et al., 1981) and/or acne and/or alopecia; biochemical hyperandrogenism was defined by increased levels of at least one serum androgen (total or free testosterone, androstenedione or dehydroepiandrosterone su…”
Background
Cited by
Items 101–162 of 162
Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome
Ferdous, J., Hossain, M., Faika, M. J., Begum, M., Mahjabeen, S., Jahan, I., Khan, M., & Hossain, M. (2025) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20251002.12 · Cited by 9
Autonomic dysfunction in polycystic ovary syndrome
Adams, Z. H., Simpson, L. L., Hart, E. C., & Lord, R. N. (2025) · Autonomic Neuroscience · doi:10.1016/j.autneu.2025.103357 · Cited by 4
Li, C., Zhou, L., Zhang, Y., Li, Y., & Zhao, L. (2024) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16076 · Cited by 4
“About 75% of PCOS women have impaired insulin function [14].”
Berbrier, D. E., Huckins, W., Berkel, E. K. V., Delage, S. I., Hannaian, S. J., Myara, R., Okafor, O. N., Chung, T. H., Tulandi, T., Reinblatt, S. L., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00286.2025 · Cited by 3
Hu, X., Zhu, M., Zhou, Q., Li, Z., Luo, L., Liang, W., Chen, S., Pu, X., & Du, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s574929 · Cited by 5
Zhao, Z., Yan, J., Ding, Y., Wang, Y., & Li, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288414 · Cited by 4
Li, Y., Han, T., Wang, Y., Gao, J., Zhang, J., Wu, Y., & Luo, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1153960 · Cited by 3
Depression in Polycystic Ovary Syndrome: Focusing on Pathogenesis and Treatment
Xing, L., Xu, J., Wei, Y., Chen, Y., Zhuang, H., Tang, W., Yu, S., Zhang, J., Yin, G., Wang, R., et al. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021032 · Cited by 4
Pharmacotherapeutic Role of Ketohexokinase in Metabolic Disorders and PCOS: A Systematic Review
Srivastava, A. K., Saxena, G., Mahawar, N., Chhabra, B., & Chitme, H. R. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01976-3 · Cited by 2
“Even though IR can occur in women of normal weight, excessive body fat, another common characteristic of PCOS women, can also exacerbate the entire clinical picture associated with IR [98].”
Almubaddil, K. H., Alotaibi, M., Mutreb, L. B., Alanazi, F., & Altulihee, M. A. (2026) · Cureus · doi:10.7759/cureus.103927 · Cited by 6
“It is important to note that, in comparison to the gold standard diagnostic techniques, HOMA-IR is an inaccurate assessment and may not be able to detect insulin resistance in women with PCOS [17].”
Polycystic ovary syndrome and metabolic syndrome: Risks in later life
Sheikh, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00019-0 · Cited by 2
Emanuel, R. H. K., Docherty, P. D., Lunt, H., Murray, R., & Campbell, R. E. (2024) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2024.100135 · Cited by 4
Goldstein, T., Ott, J., Katzensteiner, P., Krysiak, R. G., Marculescu, R., Boegl, M. S., & Hager, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247781 · Cited by 6
“However, it has nevertheless shown high sensitivity and specificity in the PCOS population, when measured against the gold standard of insulin sensitivity testing, namely the clamp test [17].”
InfluentialThe multifarious role of insulin in PCOS: From pathophysiology to therapeutic management
Moghetti, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00002-x · Cited by 3
Self-citationSaha, A., & Gupta, A. D. (2022) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20220177 · Cited by 2
“Tosi et al has demonstrated that insulin resistance, as assessed by the glucose clamp technique, is a very common feature in women with PCOS, even in normalweight subjects this finding supports our study.(17) Goodarzi et al has reported that substantial heritabilities of APAs, particularly DHEAS, have been found in th…”
ResultТатарчук, Т. Ф., Tutchenko, T. М., & Бурка, О. А. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103808 · Cited by 2
PCOS: A Weight-Inclusive and Practical Approach to Lifestyle Interventions
Mesa, D. (2022) · ADCES in Practice · doi:10.1177/2633559x221103568 · Cited by 2
Min, Z., & Yu, Y. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.07.1048 · Cited by 1
Interleukin 17 and Growth Differentiation Factor 9 Influence in a Sample of Iraqi Infertile Males.
Al-Rubaye, D., Hamza, H., & Al-Khafaji, Q. A. (2023) · PubMed Central · doi:10.22092/ari.2022.359893.2503 · Cited by 1
Common pathogenetic mechanisms of non-alcoholic fatty liver disease and polycystic ovary syndrome
Ilovayskaya, I. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-90-97 · Cited by 2
Upadhyay, S., Mazumder, A., & Das, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128382284250822045319 · Cited by 1
Berbrier, D. E., Huckins, W., Delage, S. I., Berkel, E. K. V., Hannaian, S. J., Myara, R., Okafor, O. N., Chung, T. H., Tulandi, T., Reinblatt, S. L., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2025 · Cited by 1
Biomarkers for effective prognosis of polycystic ovary syndrome: a full review
Singh, I., Pant, A., & Maurya, P. K. (2026) · Biomarkers in Medicine · doi:10.1080/17520363.2026.2622044 · Cited by 2
Gong, Z., Li, D., Li, X., Tian, J., Guo, J., Zhao, Y., Lu, Y., Gao, S., & Li, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1753316 · Cited by 1
“IR is highly prevalent occurring in 60%-90% of women with PCOS (52), and several studies have demonstrated positive correlations between HOMA-IR and CVD risk factors (53).”
Jamshaid, M., Sheikh, A. A., Jamshaid, W., Shafiq, H., & Ahmed, M. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103577 · Cited by 1
“Insulin resistance is present in 94% of obese and 60% of lean women with PCOS [32].”
Taddeo, S. D., Andreadi, A., Minasi, A., D’Ippolito, I., Borelli, B., Meloni, M., Romano, M., Ruotolo, V., Cacciotti, L., Rizzo, G., et al. (2023) · SAGE Open Medical Case Reports · doi:10.1177/2050313x231178404 · Cited by 1
Narani, M. S., Vatannejad, A., Kheirollahi, A., Teimouri, M., Bayat, S., & Jadidzadeh, F. (2023) · Acta Biochimica Iranica · doi:10.18502/abi.v1i3.14547 · Cited by 2
Resting energy expenditure in women with polycystic ovary syndrome
Tosi, F., Rosmini, F., Gremes, V., Lucarini, F., Zandonà, M., Zanolin, M. E., Fiers, T., Kaufman, J., & Moghetti, P. (2024) · Human Reproduction · doi:10.1093/humrep/deae129 · Cited by 1
Self-citationChandra, M., Vats, K., Garg, P., & Tibrewal, A. O. (2021) · International Journal of Research in Dermatology · doi:10.18203/issn.2455-4529.intjresdermatol20212548 · Cited by 3
Kokosar, M. (2018) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Patten, R. K. (2021) · Victoria University Research Repository (Victoria University) · Cited by 5
Vigna, L., Tirelli, A. S., Gaggini, M., Piazza, S. D., Tomaino, L., Turolo, S., Moroncini, G., Chatzianagnostou, K., Bamonti, F., & Vassalle, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1257473/v1
Role of Lifestyle, Diet, and Exercise in the Management of Polycystic Ovarian Syndrome
Plano, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_14
Gambineri, A., Altieri, P., & Gasparini, D. I. (2019) · Springer eBooks · doi:10.1007/978-3-030-15038-9_20
Sonntag, B. (2022) · Gynäkologische Endokrinologie · doi:10.1007/s10304-022-00454-6
“Unabhängig davon verstärkt eine Adipositas die Symptome eines PCOS oder lässt diese erst hervortreten, sodass der Nutzen einer Lebensstilmodifikation (körperliche Aktivität und Verhaltensänderung) und Gewichtsreduktion bei übergewichtigen Patientinnen für die Verbesserung der klinischen Symptome und biochemischer Mark…”
InfluentialFrequency of Insulin Resistance and Their Association with BMI in Polycyclic Ovarian Syndrome
Obaid, S., Khan, S. Z., Kakar, I. A., & Kakakhel, S. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs20221611493
Abdelsalam, H. M. (2024) · Bulletin of Faculty of Science Zagazig University · doi:10.21608/bfszu.2023.224632.1289
Urbanetz, L. A. M. L. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2024.tde-05082024-124157
Hamsho, M., Ranneh, Y., & Fadel, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endinu.2025.501578 · Cited by 4
Metabolic complications in a large cohort of Portuguese women with hirsutism-related disorders
Pinto, J., Cera, N., & Pignatelli, D. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02744-9 · Cited by 1
Novel Therapeutic Intervention for PCOS-1
Bajaj, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010010
Mo, T., Qiu, Y., He, S., Wang, G., Li, B., Shen, Q., Nie, X., Wei, J., Li, N., Pang, B., et al. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01918-6 · Cited by 1
“In a study that used a hyper-insulinaemic euglycaemic clamp, the gold standard method for measuring INS action, INS dysfunction was observed in 74.9% of women with the disease [65].”
InfluentialMudrikatin, S., Aryani, H. P., & Setyowati, R. (2026) · Jurnal Penelitian Pendidikan IPA · doi:10.29303/jppipa.v12i1.13687 · Cited by 1
“…main bioactive compounds, gingerol and shogaol, have been shown to suppress major proinflammatory mediators such as IL-6, TNF-α, and IL - 1β, while enhancing antioxidant defenses through modulation of the oxidative stress pathway (Carmona & Pereira, 2013; Marlina et al., 2023; Tosi et al., 2017).”
Состав кишечной микробиоты и эндокринно-метаболические нарушения при синдроме поликистозных яичников
Кириллова, Е. Д., Евгеньевна, Ч. Г., Алексеевна, П. В., Муравьева, В. В., & Priputnevich, T. V. (2026) · Лабораторная диагностика Восточная Европа · doi:10.34883/pi.2026.15.1.016
Houston, E. J., Jewett, E., Athar, F., & Templeman, N. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708393 · Cited by 1
“It is likely that insulin resistance and/or hyperinsulinemia, present in approximately 60-95% of women with PCOS, compounds the reproductive and metabolic characteristics of PCOS [11,12].”
Álvarez, J. P. G., Murcia, D. M. G., Reina, H. S. L., Isaac, N. G., & Torres-Pradilla, M. (2026) · Piel · doi:10.1016/j.piel.2025.12.012
Association Between Maternal PCOS and Susceptibility to Asthma in Offspring: A Narrative Review
Zhang, N., Xiao, Y., Xu, L., Zhou, Z., & Pan, J. (2026) · Current Epidemiology Reports · doi:10.1007/s40471-026-00385-x
Dikova, N. N., Andreeva, P., Dimova, I. I., & Velizarova, M. (2026) · Revista română de medicină de laborator · doi:10.2478/rrlm-2026-0016
“…reproductive, metabolic, and psychological consequences: approximately 50% of women suffer from anovulatory infertility [4,5], 75–95% exhibit insulin resistance, which is associated with hyper-androgenism and anovulation [4-6], and about 50% of cases progress to prediabetes or type 2 diabetes [5].”
Therapeutic strategies for reproductive-age women with polycystic ovary syndrome: A review
Sinchikhin, S. P., Kurbanov, B., Анатольевна, С. Н., Ruzieva, N. K., & Mamiev, O. B. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.4.203667
IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS
Buia, V., Catellani, C., Croci, S., Righi, B., Morini, D., Falbo, A. I., Nicoli, A., Fanti, A. D., Belloni, L., Aguzzoli, L., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1856759
“Moreover, PCOS is associated with systemic low-grade in fl ammation and often with insulin-resistance (70%-75% of PCOS women) (7) which contribute to PCOS comorbidities such as infertility, hyperinsulinemia, impaired glucose tolerance, type 2 diabetes, dyslipidemia, obesity, and increased…”
Röblitz, S. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0211
Shi, B., Feng, J., Lu, F., Guan, M., Yu, J., Gao, Z., Wang, Y., Cong, J., Ma, H., Han, C., et al. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s575900
“35 While our HOMA-IR assessed IR prevalence (41.99”
InfluentialTherapeutic potential of natural products in polycystic ovary syndrome
Bai, C., & Liu, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12324-6
“These pathophysiological disturbances manifest clinically as oligo-or anovulation, infertility, hyperandrogenism, polycystic ovarian morphology, and metabolic abnormalities such as IR, dyslipidemia, and overweight or obesity [15–17].”
Chen, Y., Shi, X., Ma, L., Hu, Y., Wang, M., & Shu, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1847801
Eotaxin in polycystic ovary syndrome/polyendocrine metabolic ovarian syndrome: focus on eosinophils
Acar, B. C., & Berkel, Ç. (2026) · Comparative Clinical Pathology · doi:10.1007/s00580-026-03838-3
“About 75% of women with PCOS have IR (insulin resistance) (Tosi et al. 2017).”
Herbert, S., Squires, A. P., Gilligan, C., & Woolf, K. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156433
Gambineri, A., Federici, S., Maseroli, E., Guccione, L., Bonomi, M., Fulghesu, A. M., Giordano, R., Mioni, R., Pivonello, R., Rotolo, L., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02946-9 · Cited by 1
“Patients were defined as having insulin resistance if the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index was ≥ 3 [ 19, 20].”
Self-citationVine, D. F., Moran, L., Teede, H. J., & Khomami, M. B. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100734
“IR also impacts 75% of lean individuals with PMOS, highlighting the inherent dysregulation of insulin metabolism in those with PMOS [70,71].”
Jiao, H., Hua, G. U. O., & Liu, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1909495
“In a large referral cohort, Tosi et al. reported clamp-de fi ned insulin resistance in 74.9% overall, including 59.3% of normal-weight, 77.5% of overweight, and 93.9% of obese participants (19).”
InfluentialInsulin signaling in PCOS/PMOS: molecular insights and clinical implications
Goel, A., Grover, A., & Shekhar, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1955884
Yu, C., Sun, Z., Wu, Q., Zhou, Z., Chen, W., & Xu, B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1932335
“IR status was determined from Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), calculated as fasting insulin ( m IU/mL) × fasting glucose (mmol/L)/22.5 (31, 32).”
InfluentialCheng, X., Li, Y., Zhu, M., 蔡亞潔, Wei, N., Liu, Y., & Liu, Y. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.10.002
Metadata
- Authors
- Tosi, F., Bonora, E., & Moghetti, P.
- Affiliations
- University of Verona (IT)
- Corresponding author
- Moghetti, Paolo
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-13
- Volume
- 32
- Issue
- 12
- Pages
- 2515-2521
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2763794285
- Cited by
- 163
- References
- 26
- Citations by year
- 2026: 26 · 2025: 28 · 2024: 21 · 2023: 24 · 2022: 27 · 2021: 16 · 2020: 10 · 2019: 6 · 2018: 5
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Verona
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- insulin resistance, polycystic ovary syndrome, hyperinsulinemic-euglycemic clamp, HOMA, QUICKI, Matsuda insulin sensitivity index, hyperandrogenism, menstrual disorders, obesity, normal-weight women, diagnostic accuracy, referral bias, hyperinsulinemia
- MeSH terms
- Adult, Body Weight, Female, Glucose Tolerance Test, Homeostasis, Humans, Hyperinsulinism, Insulin Resistance, Obesity, Phenotype, Polycystic Ovary Syndrome, Retrospective Studies, ROC Curve, Glucose Clamp Technique, Cohort Studies, Biomarkers, Hyperandrogenism, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.